| 摘要 |
The use of a composition for opening Chloride (ClC) channels in a mammalian subject, which comprises an effective amount of a prostaglandin compound represented by the formula (II); with the proviso that the use does not include a method of medical treatment of humans, and with the proviso that the mammalian subject is not suffering from asthma and/or constipation, is disclosed. The use of this composition for treating a condition associated with reduced permeability in a mammalian subject by opening ClC channels is also disclosed. The condition associated with reduced chloride ion permeability may be cystic fibrosis. A composition for opening ClC channels in a mammalian subject, which comprises an effective amount of a prostaglandin compound, wherein the prostaglandin compound is represented by the formula (IV), is also disclosed. The use of a prostaglandin compound as shown by general formula (I), for manufacturing a pharmaceutical composition for opening ClC channels in a mammalian subject; with the proviso that the mammalian subject is not suffering from asthma and/or constipation, is also disclosed.
|
